

<b>TRANSMITTAL FORM</b>  (to be used for all correspondence after initial filing)	Application Number	10/680,806	
	Filing Date	10/06/2003	
	First Named Inventor	John R. Walker	
	Art Unit	1646	
	Examiner Name		
Total Number of Pages in This Submission	63	Attorney Docket Number	P1057US10


ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment / Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard Receipt Reference AA-AF Copy of International Search Report
<b>Remarks</b>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Firm	Genomics Institute of the Novartis Research Foundation		
Signature			
Printed Name	Timothy L. Smith, J.D., Ph.D.		
Date	7/18/05	Reg. No.	35,367

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Signature		7/19/05	
Typed or printed name	Michelle Fecteau	Date	

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



GNF Docket Number: P1057US10

*JPW*

I hereby certify that this correspondence is being deposited with the United States Postal Service first class mail in an envelope addressed to:

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450, on 7/19/05

Genomics Institute of the Novartis Research Foundation

*infected*  
Michelle K. Fecteau

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re application of:

Customer No.: 29490

John R. Walker, et al.

Examiner:

Application No.: 10/680,806

Art Unit: 1646

Filed: October 6, 2003

For: METHODS FOR TREATING  
DRUG ADDICTION

INFORMATION DISCLOSURE  
STATEMENT UNDER 37 CFR  
§ 1.97 AND § 1.98

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Sir,

The references cited on attached form PTO-1449 are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the cited information be expressively considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97 (g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, since it is being submitted prior to the first Office Action on the merits per 37 CFR 1.97(b)(3). However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 501885. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'Tim L. Smith', with a stylized flourish at the end.

Timothy L. Smith, J.D., Ph.D.

Reg. No. 35,367

Customer No. 29490


Genomics Institute of the Novartis Research Foundation

10675 John J. Hopkins Drive

San Diego, CA 92121

858-812-1547 phone

858-812-1909 fax



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0851-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitution for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 1

**Complete if Known**

Application Number	10/680,806
Filing Date	10/06/2003
First Named Inventor	John R. Walker
Art Unit	1646
Examiner Name	
Attorney Docket Number	P1057US10

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AA	XI, Z. et al. "GABA transmission in the nucleus accumbens is altered after withdrawal from repeated cocaine." J. Neurosci. 15 April 2003, 23(8): 498-505.	
	AB	SAMAH, A.N. et al. "The rate of cocaine administration alters gene regulation and behavioral plasticity: implications for addiction." J. Neurosci. 14 July 2004, 24(28): 6362-6370.	
	AC	ZHANG, L. et al. "Cocaine-induced intracellular signaling and gene expression are oppositely regulated by the dopamine D1 and D3 receptors." J. Neurosci. 31 March 2004, 24(13): 3344-3354.	
	AD	ALBERTSON, D.N. et al. "Gene expression profile of the nucleus accumbens of human cocaine abusers: evidence for dysregulation of myelin." J. Neurochem. March 2004, 88(5): 1211-1219.	
	AE	ALVARO, J.D. et al. "Molecular and behavioral interactions between central melanocortins and cocaine." J Pharmacol Exp Ther. January 2003, 304(1): 391-399.	
	AF	DE VRIES, T.J. et al. "A cannabinoid mechanism in relapse to cocaine seeking." Nature Medicine. October 2001, 7(10): 1151-1154.	
	AG	PCT International Search Report filed 04 April 2002 for International Application No. PCT/US2002/011094	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.